302964-02-9Relevant articles and documents
A convenient new and efficient commercial synthetic route for dasatinib (Sprycel)
Suresh, Garbapu,Nadh, Ratnakaram Venkata,Srinivasu, Navuluri,Yennity, Durgaprasad
, p. 1610 - 1621 (2017)
A new and efficient synthetic route for dual-Src/Abl kinase inhibitor dasatinib (Sprycel), an anticancer drug, is described. This commercially viable process yields dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over four stages.
Scalable and impurity-free process for dasatinib: Src and BCR-Abl inhibitor
Buchappa,Sagar Vijay Kumar,Durga Prasad,Aparna
, p. 1621 - 1628 (2018/06/12)
An efficient, telescopic, impurity-free and scalable process for Bcr-Abl and Src family tyrosine kinase inhibitor for synthesis of Dasatinib with high yield and purity is described.
Dasatinib derivative with anti-tumor activity and application thereof
-
, (2017/07/12)
The invention belongs to the technical field of medicine chemistry and particularly relates to a dasatinib derivative with anti-tumor activity and application thereof. The dasatinib derivative provided by the invention has a very good inhibition effect on tyrosine kinase and has a very good application prospect for developing in the anti-tumor aspect.